CLINICAL TRIALS PROFILE FOR ARTESUNATE

505(b)(2) Clinical Trials for ARTESUNATE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00203801 ↗	Combination Antimalarials in Uncomplicated Malaria	Completed	Global Fund	N/A	2002-01-01	The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine.
New Combination	NCT00203801 ↗	Combination Antimalarials in Uncomplicated Malaria	Completed	Medical Research Council, South Africa	N/A	2002-01-01	The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine.
New Combination	NCT00203801 ↗	Combination Antimalarials in Uncomplicated Malaria	Completed	World Health Organization	N/A	2002-01-01	The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine.
New Combination	NCT00203801 ↗	Combination Antimalarials in Uncomplicated Malaria	Completed	University of Cape Town	N/A	2002-01-01	The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine.
New Combination	NCT00694694 ↗	Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.	Completed	National Institute for Medical Research, Tanzania	Phase 3	2008-06-01	This trial sets out to determine whether the combination of azithromycin and artesunate (AZ+AS) is as good as the current standard treatment for uncomplicated malaria in Tanzania, artemether-lumefantrine (AL). There are two reasons this is important 1. there are only a limited range of drug combinations which work against malaria in this area of Tanzania 2. azithromycin has antimalarial properties, but is also a broad-spectrum antibiotic, so if the combination is an effective antimalarial it might have a place where there are no diagnostic facilities as syndromic treatment for fever. Artesunate and azithromycin have both been used alone or in combination with other drugs in children in Tanzania for many years, and are considered safe. There is trial evidence for the effectiveness of this combination in adults in Asia, as well as in-vitro (laboratory) evidence that it works against the malaria parasite. The trial randomizes children with non-severe malaria to the new combination AZ+AS or the standard care arm AL. The primary outcome is the parasitological failure rate by day 28- meaning do malaria parasites get cleared, and stay cleared for at least 28 days. Secondary outcomes include safety.

All Clinical Trials for ARTESUNATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00111163 ↗	Intermittent Preventive Treatment With Antimalarials in Kenyan Infants	Completed	Bill and Melinda Gates Foundation	N/A	2004-03-01	The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
NCT00111163 ↗	Intermittent Preventive Treatment With Antimalarials in Kenyan Infants	Completed	Kenya Medical Research Institute	N/A	2004-03-01	The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
NCT00111163 ↗	Intermittent Preventive Treatment With Antimalarials in Kenyan Infants	Completed	Centers for Disease Control and Prevention	N/A	2004-03-01	The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
NCT00118807 ↗	Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children	Completed	Medical Research Council	Phase 3	2003-08-01	The purpose of this trial is to compare the effectiveness of three combination treatments for uncomplicated malaria when given in operational settings, without supervision of doses other than the first dose.
NCT00118807 ↗	Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children	Completed	National Malaria Control Programme, The Gambia	Phase 3	2003-08-01	The purpose of this trial is to compare the effectiveness of three combination treatments for uncomplicated malaria when given in operational settings, without supervision of doses other than the first dose.

Clinical Trial Conditions for ARTESUNATE

Condition Name

Condition Name for ARTESUNATE
Intervention	Trials
Malaria	109
MALARIA, FALCIPARUM	17
Falciparum Malaria	12
Plasmodium Falciparum Malaria	10

Condition MeSH

Condition MeSH for ARTESUNATE
Intervention	Trials
Malaria	199
Malaria, Falciparum	85
Malaria, Vivax	15
Carcinoma in Situ	5

Clinical Trial Locations for ARTESUNATE

Trials by Country

Trials by Country for ARTESUNATE
Location	Trials
Congo, The Democratic Republic of the	31
Mozambique	28
Burkina Faso	23
Thailand	22
Kenya	21

Trials by US State

Trials by US State for ARTESUNATE
Location	Trials
Maryland	6
California	4
Ohio	3
Kentucky	2
Florida	1

Clinical Trial Progress for ARTESUNATE

Clinical Trial Phase

Clinical Trial Phase for ARTESUNATE
Clinical Trial Phase	Trials
PHASE4	2
PHASE2	6
PHASE1	3

Clinical Trial Status

Clinical Trial Status for ARTESUNATE
Clinical Trial Phase	Trials
Completed	166
Recruiting	19
Not yet recruiting	18

Clinical Trial Sponsors for ARTESUNATE

Sponsor Name

Sponsor Name for ARTESUNATE
Sponsor	Trials
London School of Hygiene and Tropical Medicine	28
University of Oxford	24
Centers for Disease Control and Prevention	18

Sponsor Type

Sponsor Type for ARTESUNATE
Sponsor	Trials
Other	494
Industry	59
U.S. Fed	37

Artesunate: Clinical Trials, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Artesunate, a semi-synthetic derivative of artemisinin, is predominantly used in the treatment of severe Plasmodium falciparum malaria. Its clinical profile, evolving approval landscape, and market potential have attracted attention amid expanding applications and ongoing trials. This report covers recent updates in clinical trials, evaluates the current market status, analyzes competitive dynamics, and projects future growth opportunities.

---

What Are the Recent Developments in Clinical Trials of Artesunate?

Overview of Current Clinical Trials

As of Q1 2023, multiple ongoing studies investigate artesunate’s broader therapeutic potential beyond malaria, including its anti-cancer, anti-viral, and anti-inflammatory effects.

Trial Phase	Indication	Sponsor/Lead	Estimated Completion	Key Objectives
Phase II/III	Severe Malaria	WHO/NIH	2024	Efficacy comparison with quinine and artemether plus lumefantrine.
Phase II	COVID-19 related ARDS	Johns Hopkins Univ.	2023	Safety and preliminary efficacy assessment.
Phase I	Cancer (glioblastoma)	biotech startup A	2023	Tolerability and optimal dosing.
Phase II	Rheumatoid arthritis	European Pharma	2024	Anti-inflammatory effects in autoimmune disease.

Source: ClinicalTrials.gov (accessed Q1 2023).

Key Clinical Insights

• Malaria: Artesunate remains the first-line treatment for severe malaria globally, with WHO endorsing its use since 2010 (WHO 2015). New formulations and combination therapies are under evaluation to address resistance concerns.

• Anti-Cancer Potential: Early-phase trials suggest artesunate's apoptosis induction and ferroptosis inhibition in glioblastoma and leukemia models. These trials focus on dosage optimization and safety profiles.

• COVID-19 and Viral Therapies: Preliminary studies indicate potential antiviral activity, but robust Phase III data are lacking.

---

Market Analysis of Artesunate

Global Market Landscape

Region	Market Size (2022, USD millions)	CAGR (2023-2028)	Key Drivers
Africa	150	5.2%	High malaria burden; government procurement programs.
Asia-Pacific	120	6.1%	Expanding use for severe malaria and off-label uses.
Europe	50	4.3%	Growing research interest, limited commercial use.
North America	45	5.0%	Off-label and clinical trial exposures increasing.

Source: Market Research Future (2022).

Market Drivers

• Malaria Incidence: Despite declining rates, malaria remains a major public health concern, especially in sub-Saharan Africa, maintaining steady demand for artesunate.

• Resistance Patterns: Emerging parasitic resistance to artemisinin derivatives in Southeast Asia has prompted renewed interest in developing optimized formulations and combination regimens.

• Off-Label and Adjunct Uses: Investigations into artesunate’s anti-cancer, anti-viral, and anti-inflammatory effects open new therapeutic avenues.

• Regulatory Approvals: Several countries (e.g., India, South Africa) have approved generic artesunate formulations for malaria, increasing market access.

Competitive Landscape

Key Players	Market Share (Approximate, 2022)	Focus Areas
Sanofi (Artésunate)	35%	Malaria treatment formulations
Guilin pharmaceutical (China)	25%	Generic manufacturing
Pharmaceutical startups (e.g., Meryer)	15%	New delivery systems and formulations
Others	25%	off-patent products, research-driven efforts

Note: Market shares are estimates based on public procurement data.

Regulatory and Policy Impacts

• WHO Treatment Guidelines: Favor artesunate-based IV therapy for severe malaria ([WHO 2015]), promoting continuous demand.

• Patent Status: The original patent for artesunate expired in most markets by 2010, facilitating generic production and reducing costs.

• Pricing Dynamics: Artesunate remains affordable in endemic countries, though supply chain disruptions impact availability.

---

Market Projections: What Is the Future of Artesunate?

Factors Influencing Future Growth

• Expansion into Adjunct Indications: The anti-cancer potential may catalyze higher-value markets, potentially adding $200-$300 million annually from 2025 onward, per projections.

• Resistance-Driven Innovation: Development of combination therapies, new formulations (e.g., liposomal, sustained-release), and nanoparticles will enhance efficacy and compliance.

• Regulatory Advances: Approvals for new indications and formulations are anticipated in 2024–2026, especially in Europe and North America.

• Global Health Initiatives: Continued support from WHO and Gavi for malaria control sustains demand in endemic regions.

Estimated Market Size and Growth (2023-2030)

Year	Global Market (USD Millions)	CAGR (2023–2030)	Notes
2023	365	—	Base year with ongoing clinical trials
2025	460	7.0%	Increased approval of formulations, expansion into new markets
2028	610	8.4%	Entry into anti-cancer and anti-viral markets
2030	770	9.0%	Broader application in personalized medicine, combination therapies

Sources: Industry projections, market research, and clinical trial pipeline analysis.

---

Comparative Analysis of Artemisinin-Based Derivatives

Parameter	Artesunate	Artemether	Quinine	Dihydroartemisinin (DHA)
Mode of Action	Rapid parasite clearance	Similar, longer half-life	Blood schizonticide	Active metabolite of artesunate
Route of Administration	IV, IM, oral	IM, oral	Oral, IV	Oral, IV
Clinical Use	Severe malaria	Uncomplicated malaria	Severe malaria, resistant cases	Malaria, research
Patent & Licensing	Patented (until ~2010), generic	Patent expired (~2012)	Patented, generic available	Patented, generic versions exist

---

Deep Dive: Regulatory and Patent Context

• Patent Status: Artesunate patents expired globally (~2010), enabling widespread generics, reducing costs.

• Regulatory Approvals:

  • WHO endorses artesunate-based IV therapy for severe malaria.
  • The drug is registered in over 100 countries.
  • Off-label uses under clinical investigation lack formal approval but are gaining traction.

• Pricing Policies: Governments and NGOs prioritize affordable pricing for endemic countries, with generic versions costing <$0.50 per vial.

---

Deepening Application: Off-Label and Emerging Uses

Indication	Current Evidence Level	Clinical Trial Status	Potential Market Impact
Cancer (Glioblastoma)	Preliminary (In vitro, in vivo models)	Phase I/II	High-margin niche if efficacy confirmed
Viral Infections (COVID-19)	Early experimental data	Mixed; ongoing trials	Second-line or adjunct therapy, but not mainstream
Autoimmune Disorders	Limited; preclinical	Early stage	Potential for chronic therapies if safety established

---

Key Challenges and Opportunities

Challenge	Opportunity
Emerging resistance	Development of combination therapies
Limited data on non-malarial uses	Accelerated clinical trials leverage existing safety data
Regulatory hurdles in non-endemic regions	Strategic partnerships with global health organizations
Cost and supply chain in endemic regions	Investment in local manufacturing capability

---

Key Takeaways

• Clinical Pipeline: Artesunate's primary use remains treating severe malaria; however, ongoing trials exploring anti-cancer and antiviral applications may diversify its market.

• Market Dynamics: Largely driven by endemic regions with consistent demand, augmented by increased adoption in non-malarial indications propelled by promising early-phase research.

• Regulatory & Patent Environment: Patent expirations and WHO guidelines facilitate generic availability and widespread use, while regulatory approvals for new indications could significantly boost demand.

• Future Growth: Predicted to grow at a compounded rate of approximately 7–9% through 2030, reaching a potential global market size nearing $770 million.

• Strategic Opportunities: Investment in combination therapies, novel formulations, and expansion into high-margin markets like oncology can enhance long-term revenue streams.

---

FAQs

1. What are the main variables influencing artesunate’s market growth?
Market growth depends on malaria prevalence, resistance patterns, regulatory approvals, expansion into new indications, and development of innovative formulations.

2. How does artesunate compare to other artemisinin derivatives?
Artesunate is favored for severe malaria due to rapid action and ease of intravenous use, while artemether and DHA are often used for different dosing regimens, with all sharing similar efficacy profiles.

3. Are there any notable patent restrictions affecting artesunate?
Patent restrictions expired by 2010 in most regions, enabling generic manufacturers to produce affordable formulations, which support widespread distribution, especially in endemic countries.

4. What non-malarial therapeutic potentials does artesunate hold?
Preclinical and early-phase clinical studies suggest anti-cancer, anti-viral, and anti-inflammatory activities, potentially broadening its application portfolio substantially.

5. What are the primary challenges facing artesunate’s broader commercialization?
Challenges include emerging drug resistance, limited late-stage clinical data for new indications, regulatory hurdles, and the need for innovative formulations to improve efficacy and compliance.

---

References

1. WHO. (2015). Guidelines for the treatment of malaria. World Health Organization.
2. ClinicalTrials.gov. (2023). Artesunate clinical trials.
3. Market Research Future. (2022). Global Malaria Treatment Market Report.
4. Gavi, The Vaccine Alliance. (2021). Malaria treatment procurement data.
5. Liu, et al. (2021). Repurposing artesunate in oncology. Journal of Cancer Research.

---

This report offers a comprehensive insight into artesunate’s clinical development, market environment, and future prospects, providing a strategic guide for stakeholders and investors in this therapeutic domain.